News
-
University of St Andrews spin out Pneumagen has reorganized as a US-based company called NorthLinks Bio, the company said, though research will continue in Scotland. Pneumagen CEO Douglas Thomson has joined the board of the… Read more . . .
-
MannKind Corporation announced that a grant from Breakthrough T1D (formerly JDRF) will be used to support the Phase 2 INHALE-1ST trial of Afrezza in children aged 10 and up with a recent Type 1 diabetes diagnosis, which was initiated earlier… Read more . . .
-
Turin, Italy -based Kither Biotech says that a Phase 1 clinical study of its KIT2014 inhaled PDE3/4 inhibitor successfully demonstrated that the nebulized formulation was safe and well tolerated, with very limited systemic exposure. The… Read more . . .
-
SpliSense announced that it has secured up to $13 million in new funding from the Cystic Fibrosis Foundation to support an ongoing Phase 2 trial of SPL84 inhaled antisense oligonucleotide for the treatment of cystic… Read more . . .
-
According to DPI developer Iconovo, the company has now signed a strategic collaboration deal with CDMO Lonza for development of spray dried formulation of inhaled biologics. In January 2025, Iconovo said that Lonza would develop spray dried… Read more . . .
-
The FDA announced that it has approved an Rx to OTC switch for Amphastar Pharmaceutical’s Rextovy 4 mg naloxone nasal spray. Amphastar’s naloxone nasal spray was initially approved for the treatment of opioid overdose by… Read more . . .
-
According ALK, the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved use of a 1 mg dose of EURneffy adrenaline nasal spray for the treatment of anaphylaxis in children aged 4 and older who… Read more . . .
-
RDD 2026 once again gathered inhaled and nasal drug experts in Scottsdale, AZ, USA for 4 days of presentations, workshops, posters, and exhibitions focused on emerging technology, with more than 400 people participating. The conference… Read more . . .
-
Lupin Limited announced that it has partnered with Laboratorios ERN for the launch of Lupin’s Luforbec beclometasone / formoterol MDI for the treatment of asthma and COPD in Spain. Luforbec, a generic version of Chiesi’s… Read more . . .
-
MannKind Corporation announced the initiation of the Phase 2 INFLO-2 trial of its MNKD-201 nintedanib DPI in patients with idiopathic pulmonary fibrosis. The 12-week INFLO-2 study is expected to enroll approximately 210 IPF patients who… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK